Thomas Buchholz
Director/Board Member at Nucleix Ltd.
Thomas Buchholz active positions
| Companies | Position | Start | End |
|---|---|---|---|
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Director/Board Member | 2020-05-10 | - |
Career history of Thomas Buchholz
Training of Thomas Buchholz
| Tufts University School of Medicine | Doctorate Degree |
| Bucknell University | Undergraduate Degree |
Statistics
International
| United States | 3 |
| Israel | 2 |
Operational
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
| Director/Board Member | 1 |
Sectoral
| Consumer Services | 3 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
- Stock Market
- Insiders
- Thomas Buchholz
- Experience
